Tag: employees

CAMPBELL, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP for accelerating semiconductor creation, today announced that the compensation committee of the company’s board of directors has granted an aggregate of 109,000 restricted stock units (RSUs) to four newly hired employees as inducement awards under the company’s 2022 Employee Inducement Incentive Plan. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION

VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the “Grant Date”), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025.

WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective August 1, 2025, the company granted non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics^®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia’s common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders.

WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company) (Nasdaq: TVGN), today announced that it expects to receive $1 million in grant funding to advance Tevogen.AI, its artificial intelligence–powered drug discovery and development program.